載入中
NASDAQHealthcareBiotechnology
最新資料
US$7.46
−US$0.11 · -1.45%
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
前收盤價
US$7.46
−US$0.11 · -1.45%
盤中時間採用ET。市場資料可能有所延遲。
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
日內區間
目前US$7.46
52週區間
目前US$7.46
盤中時間採用ET。市場資料可能有所延遲。
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
日內區間
目前US$7.46
52週區間
目前US$7.46
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 2133.17萬 USD | 1607.93萬 USD | 1533.19萬 USD | 1362.99萬 USD | 1017.22萬 USD |
| 銷售、一般及管理費用 | 1710.24萬 USD | 1092.41萬 USD | 563.5萬 USD | 398.76萬 USD | 820.35萬 USD |
| 營業費用 | 3843.4萬 USD | 2700.34萬 USD | 2096.69萬 USD | 1761.75萬 USD | 1837.57萬 USD |
| 利息收入 | 141.25萬 USD | 115.99萬 USD | 64.98萬 USD | 43.18萬 USD | — |
| 利息支出 | — | 60.36萬 USD | 88.11萬 USD | 98.29萬 USD | 116.49萬 USD |
| 折舊和攤銷 | 23.77萬 USD | 17.17萬 USD | 11.71萬 USD | 14.79萬 USD | 8.75萬 USD |
| 營業利益 | −3843.4萬 USD | −2700.34萬 USD | −2096.69萬 USD | −1761.75萬 USD | −1837.57萬 USD |
| 淨利 | −3857.61萬 USD | −2550.25萬 USD | −2124.82萬 USD | −1848.96萬 USD | −2395.79萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$17.50
上漲空間 134.58%AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
